Lophora

Executive Summary

Lophora is a clinical-stage CNS drug discovery company based in Copenhagen, Denmark, founded in 2020. The company specializes in developing next-generation neuroactive medicines for psychiatric and neurological disorders, including depression, anxiety, PTSD, eating disorders, and substance use disorders. Its lead program, LPH-5, is a selective serotonin 5-HT2A receptor agonist that has successfully completed a Phase I first-in-human clinical trial. As a private company with no disclosed funding or valuation, Lophora operates in the competitive psychedelics space, aiming to differentiate itself through novel chemistry and targeted receptor activity. The company's early-stage pipeline and lack of public market exposure suggest a high-risk, high-reward profile dependent on successful clinical development and potential partnerships.

Upcoming Catalysts (preview)

• 2026Initiation of Phase 2 Trial for LPH-570% success
• 2026Topline Phase 1 Data Presentation at Medical Conference80% success